Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,* Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation

/pdf/acc-aha-2005-practice-guidelines-for-the-management-of-4ltfid6e9i.pdf

ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vas

Keeping pace with the stream of new data and evolving evidence on which guideline recommendations are based is an ongoing challenge to timely development of clinical practice guidelines. In an effort to respond promptly to new evidence, the American College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force on Practice Guidelines (Task Force) has created a “focused update” process to revise the existing guideline recommendations that are affected by the evolving data or opinion. New evidence is reviewed in an ongoing fashion to more efficiently respond to important science and treatment trends that could have a major impact on patient outcomes and quality of care. Evidence is reviewed at least twice a year, and updates are initiated on an as-needed basis and completed as quickly as possible while maintaining the rigorous methodology that the ACCF and AHA have developed during their partnership of >20 years.

These updated guideline recommendations reflect a consensus of expert opinion after a thorough review primarily of late-breaking clinical trials identified through a broad-based vetting process as being important to the relevant patient population, as well …

2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Peripheral arterial disease (PAD) has been estimated to reduce quality of life in approximately 2 million symptomatic Americans,1 and millions more Americans without claudication are likely to suffer PAD-associated impairment.2 PAD is a strongly age-dependent condition that contributes significantly to morbidity and healthcare expenditures in the elderly: There are 413 000 discharges per year with chronic PAD, 88 000 hospitalizations involving lower-extremity arteriography, and 28 000 discharges citing embolectomy or thrombectomy of lower-limb arteries.3 Figures for prevalence of asymptomatic PAD are several-fold higher. These figures were based on National Hospital Discharge Survey and National Vital Statistics System 1985 to 1987 US data; numbers of procedures had increased in the prior decade3 and are likely to have increased in the intervening years as the population continues to age. Even though few deaths were directly attributed to PAD, PAD has potent mortality implications. Although symptomatic disease directly affects functional capacity and quality of life by restricting ambulation, asymptomatic disease is also important, not only because it may augur risk of future compromised ambulation, lower-extremity ulcers, or need for vascular surgery or amputation, but perhaps most importantly because asymptomatic and symptomatic PAD are consistent and powerful independent predictors of coronary artery disease (CAD) and cerebrovascular disease (CBVD) events and mortality. The evidence relating PAD to prevalent and incident cardiac and cerebrovascular disease (CCVD) forms the focus of the present report.

A PubMed search (updated June 2005) covering years 1966 to 2005 yielded all abstracts with title words “peripheral artery disease,” “peripheral arterial disease,” or “peripheral vascular disease.” These were reviewed for content pertaining to co-occurrence with or prediction by PAD of atherosclerotic disease and total mortality. Additional citations were identified from bibliographies of culled articles and consultation with experts. Identified citations with original epidemiological data pertaining to the relation …

/pdf/peripheral-arterial-disease-morbidity-and-mortality-4sousy6vny.pdf

Peripheral Arterial Disease: Morbidity and Mortality Implications

Thromboangiitis obliterans (Buerger's disease).

Thromboangiitis obliterans (TAO) is a nonatherosclerotic segmental inflammatory obliterative disease that most commonly affects the small- and medium-sized arteries and veins in both upper and lower extremities. In the past, TAO was exclusively a disease confined to men; however, recently more women have been diagnosed with TAO. Most patients are heavy users of tobacco, and usually cigarette smokers.

https://journals.sagepub.com/doi/pdf/10.1177/1358863X9700200109

Mahmoud B Aqel

Papers

Thromboangiitis obliterans (Buerger's disease)